c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met

PURPOSE: Strategies to inhibit the epidermal growth factor receptor (EGFR) using the tyrosine kinase inhibitor (TKI) erlotinib have been associated with limited clinical efficacy in head and neck squamous cell carcinoma (HNSCC). Co-activation of alternative kinases may contribute to erlotinib resist...

Full description

Saved in:
Bibliographic Details
Main Authors: Stabile, Laura P., He, Guoqing, Lui, Vivian Wai Yan, Henry, Cassandra, Gubish, Christopher T., Joyce, Sonali, Quesnelle, Kelly, Siegfried, Jill M., Grandis, Jennifer R.
Format: Artigo
Language:Inglês
Published: 2012
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3549019/
https://ncbi.nlm.nih.gov/pubmed/23213056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-1555
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items